Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$397.48 USD
-0.22 (-0.06%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $397.50 +0.02 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
Price, Consensus and EPS Surprise
VRTX 397.48 -0.22(-0.06%)
Will VRTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for VRTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VRTX
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Vertex Pharmaceuticals (VRTX) Falls More Steeply Than Broader Market: What Investors Need to Know
VRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
Other News for VRTX
J&J, Roche, AstraZeneca poised to have highest orphan drug sales by end of decade
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
Interesting VRTX Put And Call Options For June 7th
Vertex announces European Commission approval for KALYDECO
Cantor Fitzgerald healthcare analysts hold an analyst/industry conference call